

Stakeholder Opinions: Diabetic Renal Disease

Published: 2008-NOV-05

Pages: 88

Format: PDF & SlidePack

Price: 3800 USD

Description

Introduction

Prevalence of diabetic renal disease is on the rise. Current treatment focuses on the management of hypertension and glycemic control, but is unable to address the deterioration of renal function. An unmet need exists for therapies fully reversing disease progression. Early diagnosis can help to prevent the disease progression but lack of early diagnostic markers makes this option rather remote.

Scope

*What are the current definitions, pathophysiological stages and the natural history of progression of diabetic renal disease?

*What are the currently available diagnostic methods, the issues and the unmet needs in diagnosis and early detection of diabetic renal disease?

*What are the available treatment approaches in the early stages of diabetic renal disease, the unmet needs and the future trends?

*What are the treatment options in advanced stages of diabetic renal disease and the changing role of renal dialysis and kidney transplantation?

Highlights

Diabetic nephropathy, which is one of the most serious complications of diabetes, develops in approximately 50% of patients with type 1 diabetes mellitus who have had diabetes for 20 years. Although it is less prevalent in type 2 diabetes, clinically significant renal disease still develops in 1520% of type 2 diabetes individuals.

Most diabetic renal disease patients are suffering from type 2 diabetes, and are therefore diagnosed late once the disease has already reached its advanced, irreversible stages. This highlights one of the major issues in diabetic renal disease: the need for early diagnosis and good diagnostic markers and risk scores.

The only available treatment in advanced stages of diabetic renal disease is renal replacement therapy. Dialysis comes at a high cost and significantly reduces the patient's quality of life. Hence, it is clear that the main focus of clinicians is on the prevention of disease progression through stringent glycemic and blood pressure control.

Reasons to Purchase

*Understand current definitions, diagnostic methods and treatment approaches in diabetic renal disease

*Current challenges and future opportunities in diabetic renal disease management

*Differences, advantages and disadvantages of pharmacological and non-pharmacological disease management

Table of Contents

ABOUT DATAMONITOR HEALTHCARE 2

About the cardiovascular analysis team 2

CHAPTER 1 EXECUTIVE SUMMARY 3

BioMarket Group - A Global Online Aggregator of Life Science Market Research

Scope of the analysis	3
Datamonitor insight into available therapies in advanced heart failure	4
Contributing experts	5
CHAPTER 2 BACKGROUND	7
Diabetes mellitus	7
Definition	7
Segmentation of diabetes	8
Type 1 diabetes	8
Type 1.5 diabetes	8
Type 2 diabetes	9
Mechanisms of development of diabetes	9
Genetic or acquired causes	10
Diabetic complications	10
Microvascular complications	12
Retinopathy	12
Neuropathy	14
Nephropathy	17
Macrovascular complications	21
Effect of macrovascular complications on type 2 diabetes treatment	23
End-stage disease considerations	24
Co-morbidities	25
Obesity	25
Effect of obesity on type 2 diabetes treatment	27
Hypertension	27
Dyslipidemia	28
CHAPTER 3 DIABETIC RENAL DISEASE - DEFINITIONS AND OVERVIEW	30
Diabetic renal disease and diabetic nephropathy	30
Etiology of diabetic nephropathy	32
Etiological factors influencing the development of diabetic renal disease	32
Pathogenesis and natural history of renal nephropathy	33
Microalbuminuria	34
Pathophysiological role of hyperglycemia	36
Pathophysiological role of hypertension	37
Macroalbuminuria and end stage renal disease	38
Chronic kidney disease and cardiovascular risk	39
Diagnosis	40
CHAPTER 4 TREATMENT STRATEGIES	46
Pharmacotherapy	46
Glycemic control	47
Managing hypertension	51
Benefits of ACE inhibition	52
Data supporting the renoprotective benefits of ACE inhibitors.	53
Benefits of angiotensin II receptor blockade	57
Renin inhibitors	61
Diuretics	65
Calcium channel blockers	65
Diet and protein restriction	66
Renal replacement	67
Dialysis	68
Hemodialysis	68
Peritoneal dialysis	70
Renal transplantation	71
Cultural issue	73
CHAPTER 5 COMMERCIAL OPPORTUNITIES	74
Battle of the antihypertensives	74
Rationale for the renin-angiotensin combinations	75
Development of new agents	77
APPENDIX	79
Report methodology	79
Bibliography	79
About Datamonitor	83
About Datamonitor Healthcare	83
About the cardiovascular analysis team	84
Disclaimer	85
List of Tables	
Table 1: Framingham Heart Study data on percentage lipid levels in men and women with and without diabetes	29
Table 2: Stages of diabetic nephropathy: cut-off values of urine albumin for diagnosis and main clinical characteristics	36
Table 3: Stages of chronic kidney disease	38
Table 4: Cardiovascular risk according to stages of chronic kidney disease	39
Table 5: Pharmacokinetic profiles of commercially available angiotensin II receptor blockers (ARBs)	59
List of Figures	
Figure 1: Proportion of type 2 diabetics with complications in the seven major markets, 2007	11
Figure 2: Proportion of type 2 diabetics with complications that suffer from microvascular and/or macrovascular complications in the seven major markets, 2007	12
Figure 3: Proportion of type 2 diabetics with retinopathy in the seven major markets, 2007	13
Figure 4: Average time required for the development of diabetic retinopathy in the seven major markets, 2007	14

BioMarket Group - A Global Online Aggregator of Life Science Market Research

Figure 5: Proportion of type 2 diabetics with neuropathy in the seven major markets, 2007 16

Figure 6: Average time required for the development of diabetic neuropathy in the seven major markets, 2007 17

Figure 7: Proportion of type 2 diabetics with different stages of nephropathy in the seven major markets, 2007 19

Figure 8: Average time from the diagnosis of diabetes required for the development of different stages of diabetic nephropathy in the seven major markets, 2007 20

Figure 9: Proportion of type 2 diabetics with macrovascular complications in the seven major markets, 2007 22

Figure 10: Average time for the development of macrovascular complications in the seven major markets, 2007 23

Figure 11: Proportion of type 2 diabetics with serious complications (e.g. end-stage renal disease, acute myocardial infarction, amputation), 2007 25

Figure 12: Treatment algorithm for type 2 diabetes, recommended by the 2006 ADA/EASD clinical practice guidelines 50

Figure 13: Mechanism of action of ACE inhibitors 53

Ordering

Order Online - <http://www.biomarketgroup.com/market-research-report/stakeholder-opinions-diabetic-renal-disease.html>

Order by Fax - using the form below

Order by Post - print the order form below and send to:

BioMarket Group
Björnnäsvägen 21
11419 STOCKHOLM
SWEDEN

Fax Order Form

To place an order via fax simply print this form, fill in the information below and fax the completed form to +46-8-56849191. If you have any questions please visit

<http://www.biomarketgroup.com/index.php/contacts/>

Order Information

Please verify that the product information is correct:

Product Name: **Stakeholder Opinions: Diabetic Renal Disease**

Web Address: <http://www.biomarketgroup.com/market-research-report/stakeholder-opinions-diabetic-renal-disease.html>

Format: PDF & SlidePack

Price: 3800 USD (Single User License)

Delivery of hard copy or CD-ROM is subject to a Courier charge of 50 USD.

Delivery within Sweden is subject to VAT at 25%.

Contact Information

Please enter all the information below in **BLOCK CAPITALS**

Title: _____

Name: _____

Email Address:* _____

Job Title: _____

Organization: _____

EU companies must supply: VAT / BTW / MOMS

MWST / IVA / FPA number:

Address: _____

Zip Code: _____

City: _____

State: _____

Country: _____

Phone Number: _____

Fax Number: _____

Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

- Pay by credit card:**
- American Express
 - Master Card
 - Visa

Cardholder Name: _____

Expiry Date (MM/YY): _____

Card Number: _____

CVV Number: _____

- Pay by check:**

Please post the check, accompanied by this form, to:
BioMarket Group
Björnnäsvägen 21
11419 STOCKHOLM
SWEDEN

- Pay by wire transfer:** Please transfer funds to:

Account number: 43521169

Swift code: HANDSESS

IBAN number: SE74 6000 0000 0000 4352 1169

Bank Address: Handelsbanken, Stockholm, Sweden

If you have a Marketing Code please enter it below:

Marketing Code: _____

Please supply purchase order number if needed:

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, Gmail)

Please note that by ordering from BioMarket Group you are agreeing to our Terms and Conditions at

<http://www.biomarketgroup.com/index.php/biomarket-group-full-terms-and-conditions>

Please fax this form to: +46-8-56849191